Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.
Department of Pathology, School of Medicine, Minia University, Minia, Egypt.
PLoS One. 2022 Nov 14;17(11):e0277266. doi: 10.1371/journal.pone.0277266. eCollection 2022.
BACKGROUND AND AIMS: So far, few clinical trials are available concerning the role of growth hormone receptor (GHR)/signal transducer and activator of transcription 5 (STAT5)/insulin like growth factor-1 (IGF-1) axis in hepatocarcinogenesis. The aim of this study was to evaluate the hepatic expression of GHR/STAT5/IGF-1 signaling pathway in hepatocellular carcinoma (HCC) patients and to correlate the results with the clinico-pathological features and disease outcome. The interaction between this signaling pathway and some inducers of epithelial-mesenchymal transition (EMT), namely Snail-1 and type 2 transforming growth factor-beta receptor (TGFBR2) was studied too. MATERIAL AND METHODS: A total of 40 patients with HCV-associated HCC were included in this study. They were compared to 40 patients with HCV-related cirrhosis without HCC, and 20 healthy controls. The hepatic expression of GHR, STAT5, IGF-1, Snail-1 and TGFBR2 proteins were assessed by immunohistochemistry. RESULTS: Compared with cirrhotic patients without HCC and healthy controls, cirrhotic patients with HCC had significantly lower hepatic expression of GHR, STAT5, and IGF-1proteins. They also displayed significantly lower hepatic expression of TGFBR2, but higher expression of Snail-1 versus the non-HCC cirrhotic patients and controls. Serum levels of alpha-fetoprotein (AFP) showed significant negative correlations with hepatic expression of GHR (r = -0.31; p = 0.029) and STAT5 (r = -0.29; p = 0.04). Hepatic expression of Snail-1 also showed negative correlations with GHR, STAT5, and IGF-1 expression (r = -0.55, p = 0.02; r = -0.472, p = 0.035, and r = -0.51, p = 0.009, respectively), whereas, hepatic expression of TGFBR2 was correlated positively with the expression of all these proteins (r = 0.47, p = 0.034; 0.49, p = 0.023, and r = 0.57, p<0.001, respectively). Moreover, we reported that decreased expression of GHR was significantly associated with serum AFP level>100 ng/ml (p = 0.048), increased tumor size (p = 0.02), vascular invasion (p = 0.002), and advanced pathological stage (p = 0.01). Similar significant associations were found between down-regulation of STAT5 expression and AFP level > 100 ng/ml (p = 0.006), vascular invasion (p = 0.009), and advanced tumor stage (p = 0.007). Also, attenuated expression of IGF-1 showed a significant association with vascular invasion (p < 0.001). Intriguingly, we detected that lower expression of GHR, STAT5 and IGF-1 were considered independent predictors for worse outcome in HCC. CONCLUSION: Decreased expression of GHR/STAT5/IGF-1 signaling pathway may have a role in development, aggressiveness, and worse outcome of HCV-associated HCC irrespective of the liver functional status. Snail-1 and TGFBR2 as inducers of EMT may be key players. However, large prospective multicenter studies are needed to validate these results.
背景与目的:迄今为止,关于生长激素受体(GHR)/信号转导子和转录激活子 5(STAT5)/胰岛素样生长因子 1(IGF-1)轴在肝癌发生中的作用的临床试验很少。本研究旨在评估肝细胞癌(HCC)患者肝组织中 GHR/STAT5/IGF-1 信号通路的表达,并将结果与临床病理特征和疾病结局相关联。还研究了该信号通路与上皮-间充质转化(EMT)的一些诱导物之间的相互作用,即 SNAI1 和转化生长因子-β受体 2(TGFBR2)。 材料与方法:本研究纳入了 40 例 HCV 相关性 HCC 患者,并与 40 例无 HCC 的 HCV 相关肝硬化患者和 20 例健康对照者进行比较。采用免疫组织化学法检测 GHR、STAT5、IGF-1、SNAI1 和 TGFBR2 蛋白在肝组织中的表达。 结果:与无 HCC 的肝硬化患者和健康对照组相比,伴有 HCC 的肝硬化患者肝组织中 GHR、STAT5 和 IGF-1 蛋白的表达明显降低。他们还显示出明显较低的 TGFBR2 肝表达,但 SNAI1 的表达较高,与无 HCC 的肝硬化患者和对照组相比。血清甲胎蛋白(AFP)水平与 GHR(r = -0.31;p = 0.029)和 STAT5(r = -0.29;p = 0.04)的肝表达呈显著负相关。SNAI1 的肝表达也与 GHR、STAT5 和 IGF-1 的表达呈负相关(r = -0.55,p = 0.02;r = -0.472,p = 0.035 和 r = -0.51,p = 0.009),而 TGFBR2 的肝表达与这些蛋白的表达呈正相关(r = 0.47,p = 0.034;r = 0.49,p = 0.023 和 r = 0.57,p < 0.001)。此外,我们报告 GHR 表达降低与血清 AFP 水平>100ng/ml(p = 0.048)、肿瘤增大(p = 0.02)、血管侵犯(p = 0.002)和晚期病理分期(p = 0.01)显著相关。STAT5 表达下调与 AFP 水平>100ng/ml(p = 0.006)、血管侵犯(p = 0.009)和晚期肿瘤分期(p = 0.007)也存在显著关联。IGF-1 表达减弱与血管侵犯显著相关(p < 0.001)。有趣的是,我们发现 GHR、STAT5 和 IGF-1 的低表达被认为是 HCV 相关 HCC 预后不良的独立预测因素。 结论:GHR/STAT5/IGF-1 信号通路的表达降低可能在 HCV 相关 HCC 的发生、侵袭性和预后不良中起作用,而与肝功能状态无关。SNAI1 和 TGFBR2 作为 EMT 的诱导物可能是关键因素。然而,需要更大规模的前瞻性多中心研究来验证这些结果。
Horm Metab Res. 2018-2
Gastroenterology. 2005-5
Onco Targets Ther. 2021-1-28
World J Hepatol. 2020-11-27
Mol Cell Endocrinol. 2020-12-1
Arch Endocrinol Metab. 2019
Hepatoma Res. 2019
BMC Gastroenterol. 2019-5-2